IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
79 hedge funds and large institutions have $186M invested in IGM Biosciences in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 14 closing their positions.
1,511% more call options, than puts
Call options by funds: $145K | Put options by funds: $9K
29% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 21
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 79 → 79 (0)
3.66% less ownership
Funds ownership: 71.55% → 67.89% (-3.7%)
10% less capital invested
Capital invested by funds: $208M → $186M (-$21.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$3.85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.72M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.68M |
| 4 |
First Manhattan
New York
|
+$1.46M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$4.02M |
| 2 |
Millennium Management
New York
|
-$1.84M |
| 3 |
Goldman Sachs
New York
|
-$1.83M |
| 4 |
D.E. Shaw & Co
New York
|
-$846K |
| 5 |
Renaissance Technologies
New York
|
-$722K |
IGMS Hedge Fund Activity: Q3 2023 in Review
79 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2023, worth a combined $186M — down 10% from $208M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new IGMS positions and 14 closed out — a net gain of 1 holder — while 27 added to existing stakes and 21 trimmed.
The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $3.85M. The largest seller was UBS AM, cutting an estimated $4.02M.
- 79 institutional investors held IGM Biosciences (IGMS) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $186M of IGM Biosciences stock for Q3 2023, down 10% quarter-over-quarter.
- 15 funds opened new IGM Biosciences positions in Q3 2023 and 14 closed out, a net change of +1 holder.
- The largest IGM Biosciences buyer in Q3 2023 was ExodusPoint Capital Management, an estimated $3.85M added.
- The largest IGM Biosciences seller in Q3 2023 was UBS AM, an estimated $4.02M sold.
Based on aggregated 13F filings for Q3 2023.